Key Highlights

  • MMED shares are trading up 7.44% to $24.09, near a fresh 52-week high.
  • BTIG raised its price target to $28 from $25 while maintaining a Buy rating.
  • The company's fiscal Q1 2027 report, released September 1, showed net sales rising 16.6% to $843 million, beating estimates, with Operating Income swinging to a $5 million profit from a $13 million loss a year earlier.
  • Management raised full-year organic Revenue growth guidance to approximately 10.5%, citing strong Demand for MiniMed Flex and MiniMed Go.
  • BlackRock disclosed a 7,527.5% increase in its stake, adding to broader institutional buying interest.

Post-Earnings Rally Extends on Fresh Price Target Hike

MiniMed Group (NASDAQ:MMED) shares are extending their post-earnings rally, climbing toward a fresh 52-week high after BTIG raised its price target to $28 from $25 while maintaining a Buy rating. MiniMed is a global medical technology company that develops, manufactures, and markets an integrated portfolio of diabetes management solutions, including automated insulin delivery systems, insulin pumps, continuous glucose monitors, and its CareLink software platform, following its Spinoff from Medtronic in March 2026.

Fiscal Q1 Beat and Raised Guidance Underpin the Move

The company's fiscal first-quarter 2027 report, released September 1, showed net sales rising 16.6% year over year to $843 million, ahead of the $826.8 million consensus estimate, with operating income swinging to a $5 million profit from a $13 million loss a year earlier. Organic revenue growth reached 15.8%, with U.S. growth accelerating to 13.1% from 1.5% in the prior quarter, driven by more than 20% year-over-year growth in new pump sales following the late-June U.S. launch of MiniMed Flex and a 24% increase in new prescribers.

Pipeline Progress and Institutional Buying Add Momentum

Management raised full-year fiscal 2027 organic revenue growth guidance to approximately 10.5% from roughly 10% previously and reaffirmed adjusted EBITDA Margin guidance of approximately 16% for the year. The company's MiniMed Fit patch pump completed its FDA submission ahead of schedule, targeting a full U.S. launch by summer 2027, while its Vivera closed-loop algorithm completed pivotal trial enrollment ahead of schedule. Institutional buying has also been in focus, with BlackRock disclosing a 7,527.5% increase in its stake and other funds, including Freestone Grove Partners, initiating new positions.

Lock-Up Expiration Remains a Watch Item

MiniMed shares are climbing as investors reward the raised guidance and growing institutional interest, though a large lock-up agreement covering more than 252 million shares expired September 2, which could add to share Supply in the sessions ahead. Continued execution on the MiniMed Flex and MiniMed Go launches, alongside progress on the Vivera closed-loop system, will likely remain the key drivers for the stock.